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ABSTRACT 
 
We tested the effectiveness of PTK787/ZK 222584, an inhibitor of the vascular 
endothelial growth factor (VEGF) receptor tyrosine kinases, when applied together with 
radiation on canine oral melanoma xenografts. Xenografts were treated with radiotherapy (4 x 
6 Gy), PTK787/ZK 222584, or with a combination of both. Treatment efficacy was assessed 
using a tumour growth delay assay, serial power Doppler and pO2 measurements during and 
after therapy. There was a significant growth delay for the group treated with radiation alone 
and for the combined treatment group; however, tumour growth delay was similar in both 
groups. Tumours were hypoxic before irradiation and no significant re-oxygenation occurred 
during therapy. In all tumours, vascularity and perfusion were significantly lower at the end of 
the study but no significant differences in perfusion, vascularity and oxygenation status were 
observed between and within treatment groups. The combination of PTK787/ZK 222584 and 
radiotherapy was not advantageous over radiotherapy alone in this model.  
 
 
 
Keywords: canine melanoma xenograft, PTK787/ZK 222584, radiotherapy, power Doppler 
ultrasonography, pO2
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INTRODUCTION 
 
Angiogenesis, the process of new blood vessel formation, is a rare phenomenon in 
healthy adults, occurring only locally and transiently under distinctive physiological 
conditions such as wound healing, inflammation, and the female reproductive cycle. In 
contrast, the switch to an angiogenic phenotype is known to be critical for tumour 
progression. Unless a tumour can stimulate the formation of new blood vessels, it remains 
restricted to a microscopic size (Folkman, 1995).  
 
A variety of very potent angiogenic activators are commonly expressed in many 
tumour types and enhance the proliferation of both endothelial and tumour cells (Graeven et 
al., 2001; Rofstad and Halsor, 2000). Among them, vascular endothelial growth factor 
(VEGF) is considered as one of the major and best studied molecules responsible for tumour 
angiogenesis (McMahon, 2000). Therefore, it is reasonable to inhibit tumour angiogenesis 
and especially the VEGF/VEGFR signalling pathway as a new method of tumour treatment. 
This treatment is mainly targeting immature blood vessels, which are dependent on constant 
VEGF signalling for survival (Benjamin et al., 1999). Many studies recommend a 
combination of angiogenesis inhibitors with conventional therapies, e.g. with chemotherapy 
(Baker et al., 2002; Teicher et al., 1992) or ionizing radiation (Wachsberger et al., 2003). A 
class of drugs that holds promising results is small inhibitory molecules that block the 
receptor tyrosine kinase signalling pathways. Among them, PTK787/ZK 222584 is an orally 
bioavailable, potent and selective inhibitor of all VEGFR-tyrosine kinases. In murine 
xenograft models, PTK787/ZK 222584 showed good efficacy in inhibiting the growth of 
human carcinomas when given alone (Drevs et al., 2000; Wood et al., 2000) or in 
combination with chemo- or radiation therapy (Baker et al., 2002; Hess et al., 2001). In a 
xenograft mouse model the vasculature is build by the host organism (Folkmann et al. 1995) 
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allowing the tumour to grow. The pharmacological activity of PTK787/ZK 222584 on the 
vasculature of nude mice has been demonstrated (Lee, 2005, Wood et al., 2000).  
Malignant melanoma is the most common oral tumour in dogs and is considered a 
very aggressive local and systemic disease with a poor prognosis. Conventional therapy is 
limited and usually consists of palliative treatment such as surgery and/or radiation therapy to 
gain local control (Withrow, 2001). We have previously shown that plasma VEGF is elevated 
in dogs with tumours including melanoma (Wergin and Kaser-Hotz, 2004) implying that the 
inhibition of the VEGF/VEGFR signalling pathway together with ionizing radiation might be 
a useful way of improving local control of the tumour and to increase survival time of patients 
affected with this aggressive disease. 
 
We therefore designed a canine malignant melanoma xenograft model in mice to 
assess if PTK787/ZK 222584 given before each fraction of radiation therapy would have an 
additive effect. A clinically relevant and effective dose of ionizing radiation combined with a 
dose of PTK787/ZK 222584 previously shown to have a radio-sensitising effect in vitro and 
in vivo (Hess et al., 2001) was given. With this combined treatment approach we expected to 
see changes in tumour vascularity and oxygenation. Therefore, serial contrast-enhanced 
power Doppler ultrasonography was performed to monitor changes in tumour vascularity and 
perfusion. At the same time points, the intra-tumoural oxygen tension was determined since 
hypoxia is considered to be one of the major factors leading to radio-resistance of tumour 
cells. 
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MATERIALS AND METHODS 
 
Establishing a Melanoma Cell Line. 
We established the M2 cell line from a primary malignant oral amelanotic melanoma 
of an 11-year-old male Golden Retriever dog. Immediately after surgery, a tumour biopsy was 
dissected and digested with 0.1% collagenase, 0.05% protease Type I and 0.002% DNAse (all 
obtained from Sigma) and diluted in Dulbecco’s modified Eagle’s medium (DMEM) (Life 
technologies, Inc.). The resulting single cell suspension was washed with PBS and incubated 
in DMEM supplemented with GlutaMax, sodium pyruvate, non-essential amino acids, 
antibiotics (Penicillin/Streptomycin, 1 x final conc.) (all purchased from Life Technologies, 
Inc.) and 20% heat-inactivated foetal calf serum (FCS) (Boehringer Mannheim GmbH). Cells 
were cultured at 37°C in a humidified atmosphere with 5% CO2. After 5 passages, the 
concentration of FCS was gradually reduced to 10%. Immunohistochemistry of the original 
tumour tissue revealed reactivity with antibodies against the melanoma-specific antigens 
MelanA and PNL2. Immunohistochemistry of cultured cells with antibodies against MelanA 
and PNL2 yielded a positive result in over 20% of the cells at passage 3. Tumourigenicity was 
confirmed by subcutaneous injection of 1x107 M2 cells in the left flank region of four six-
week-old female Swiss nu/nu mice (Charles River Laboratories). Histopathological analysis 
of xenograft tumour tissue revealed a melanocytic cell type similar to the original tumour. In 
addition, a band of the expected size was amplified in a PCR with canine-specific primers for 
p53 exon 5 from extracts of xenograft tissue but not from tissue samples originated from a 
mouse lymph node, indicating that the tumour tissue was indeed of canine origin. 
 
In vivo tumour model. 
Four-week-old, female Swiss nu/nu mice, caged in groups of five to six animals, were 
treated according to institutional guidelines approved by the Kantonales Veterinäramt Zürich. 
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For the establishment of xenografts, 100 µl of a single cell suspension of subconfluent M2 
canine melanoma cells was inoculated subcutaneously within the left upper thigh region (total 
number of animals = 36). Tumour size was measured with a calliper twice a week, and 
tumour volume was estimated according to the formula: volume = ½ x length x width2. Mice 
were sacrificed by cervical dislocation when tumours reached a volume of 1500 ± 150 mm3. 
Tumour tissue was immediately resected and snap-frozen in isopentane (Fluka)/liquid 
nitrogen and stored at – 80°C.  
 
Treatment. 
When tumours reached a volume of 500 ± 50 mm3, animals were randomly assigned 
into four groups (n= 8-11) and treated as following: group 1: oral application of PTK787/ZK 
222584 (Novartis AG, Schering AG); group 2: radiation; group 3: radiation in combination 
with PTK787/ZK 222584; group 4: untreated control. PTK787/ZK 222584 was given on four 
consecutive days at a dosage of 100 mg/kg body weight. The drug (5 mg/mL) was suspended 
in 5% DMSO, 1% Tween 80 and given orally. Radiation treatment was applied using 6 MeV 
electrons from a linear accelerator (Dynaray LA20, ABB, Varian). In order to achieve a 
homogenous dose build up and distribution, a one cm bolus was placed over the irradiated 
field. Treatment was given in four 6 Gy fractions on consecutive days. Mice were 
anaesthetised with intra-peritoneal injections of ketamine (100 mg/kg, Vétoquinol) and 
xylazine (20 mg/kg, Streuli) and positioned on a heating pad during the procedure. In the 
combined treatment group, PTK787/ZK 222584 was administered 30 minutes prior to 
radiation. 
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Tumour Growth Delay Assay. 
Treatment efficacy was assessed using a tumour growth delay assay. Tumour growth 
delay was defined as the mean time for tumours in the treated groups to reach 1500 mm3 
minus the time for the control group to reach the same size. 
 
Power Doppler Ultrasonography and pO2 Measurements. 
Contrast-enhanced power Doppler ultrasonography (US) and subsequent pO2 
measurements were performed immediately prior to the first and fourth treatment, on days 
four and eight post-treatment and when tumours had reached their final size. All mice were 
anaesthetised and handled as described above. Imaging was performed using a 5 - 12 MHz 
linear transducer (ATL 5000, Philips AG). Power Doppler settings were held constant across 
all examinations (colour gain 81%, medium wall filter, 500 Hz pulse repetition frequency, 
low velocity flow estimation, maximal depth 25 mm, frame rate 10 - 12 Hz). The ultrasound 
contrast agent was a first-generation microbubble suspension (Levovist, Schering AG (400 
mg/mL)). Initial scanning of the entire tumour was performed with B-mode to define its 
boundary and morphology. A rectangular sample volume was then placed over the tumour 
and immediate surrounding tissue, denoting the region in which power Doppler data would be 
acquired. After the slow intravenous injection of 0.1 mL contrast medium, a minimum of five 
power Doppler images was obtained throughout the tumour after blooming artefacts had 
disappeared. Computerized image analysis was performed using a dedicated software (Qwin, 
Leica Microsystems AG) and similar to the method by Fleischer et al. (1999), three 
parameters were computed for each region of interest: fractional area (FA), mean colour level 
(MCL), and colour-weighted fractional area (CWFA). FA represents a vascularity index and 
both MCL and CWFA assess perfusion. Computerized parameters were determined for post-
contrast power Doppler by calculating the median of each set of five images.  
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Using a sterile needle electrode (Helzel Medical System) tumour oxygen tensions were 
measured polarographically after the ultrasound procedure as described elsewhere 
(Achermann et al., 2002; Höckel et al., 1991; Kallinowski et al., 1990; Vaupel et al., 1991). 
The needle electrode was placed within the tumour tissue and after an adaptation time, at least 
30 values were collected in 1 – 2 different tracks. The measurement inaccuracy of the device 
was +/- 1.5 mm Hg and negative values of ≥ -1.5 mmHg were defined as pO2 = 0 mmHg. 
Data, which consisted of less than 10 reliable readings, were not used for statistical analyses.  
 
Statistical Analysis. 
Experimental data is presented as means ± standard deviation unless otherwise stated 
and 95% confidence intervals of the means (95% CI). Statistical comparison of means 
between treatment groups was performed using Kruskal-Wallis test or one-way ANOVA with 
post-hoc tests (Bonferroni Dunn method) for normally distributed data. If necessary, variables 
were transformed using the natural logarithm. For the tumour growth delay analysis, the 
difference of the means together with the corresponding 95% CI were calculated according to 
Sachs (Sachs, 1997). For serial ultrasound and pO2 measurements, differences of values at a 
certain time point during or after treatment to the baseline values (prior to treatment) were 
calculated to eliminate variability of the baseline values. In order to assess multiple 
measurements over time in the same animal, repeated measures analysis with the Greenhouse-
Geisser correction was used in order to analyse the differences in vascularity, perfusion and 
pO2 between treatment groups and to determine their association with time. A P-Value < 5% 
was considered significant. Statistical analysis was performed with StatView (SAS Institute 
Inc., Version 6.0.1) and SPSS (SPSS Schweiz AG, Version 10.8). 
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RESULTS 
 
Effect of PTK787/ ZK222584 and Ionizing Radiation on Growth of Canine Melanoma 
Xenografts.  
Treatment was initiated when M2 xenografts reached a volume of 500 ± 50 mm3 (after 
a mean of 90.8 ± 15.9 days). PTK787/ZK 222584 alone did not significantly delay tumour 
progression compared to the untreated control group. In contrast, radiation therapy as well as 
the combined treatment of radiation and PTK787/ZK 222584 caused a highly significant 
growth delay compared to the control group (Fig. 1A). The mean tumour growth delay of 
treated tumours to triplicate their volume was 30.2 days (95% CI: 18.3, 42.0) in the radiation 
group and 30.9 days, (95% CI: 18.4, 43.4) in the combined treatment group (P < 0.0001). 
Tumour growth delay was similar in the group treated with radiation alone and for the 
combined treatment group. The mean tumour growth delay in the PTK787/ZK 222584-treated 
group was only 0.63 days compared to the control, (95% CI: -8.2, 9.5) (Fig. 1B).  
 
Treatment Effect on Tumour Vascularity and Perfusion. 
Prior to treatment, low median values were found for vascularity (FA: 7.24%) and 
perfusion (CWFA: 3.22, MCL: 38.41). Concerning perfusion (CWFA) of tumours, neither an 
influence of time (P = 0.773) nor differences between groups (P = 0.931) were found during 
and after treatment (Fig. 2A). Similar results (P = 0.787 and P = 0.893, respectively) were 
found for the vascularity parameter FA (Fig. 2B). However, at the end of the experiment, all 
tumours were significantly less vascularised and perfused than prior to treatment (P = 0.0013 
for CWFA and P = 0.0002 for FA) (Fig. 2, 3). 
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Tumour Oxygenation During and After Therapy. 
The mean pO2 of all tumours at the beginning of the study was 2.4 mmHg, (95% CI: 
1.3, 3.5). PO2 readings below 2.5 mm Hg were measured in 63% of the tumours, values below 
5 mm Hg in 73%. Although not statistically significant, a mild increase in tumour 
oxygenation was observed in all treatment groups during therapy, whereas thereafter, pO2 
gradually decreased in all tumours. No significant changes of the pO2 were found between 
and within groups (Table 1). 
 
 
DISCUSSION 
 
Malignant melanoma in the oral cavity of dogs is an aggressive local and systemic 
disease with a poor prognosis. Established treatment methods such as surgery and/or radiation 
therapy are palliative and limited to local control (Rassnick et al., 2001). Hence, the 
development of new treatment strategies to improve survival is needed urgently. The 
importance of VEGF for progression and metastasis of human melanoma has been 
demonstrated (Graeven et al., 2001; Rofstad and Halsor, 2000). Since VEGF protein has been 
shown to be augmented in the plasma of tumour bearing dogs including melanoma (Wergin 
and Kaser-Hotz, 2004), we aimed at exploring the effectiveness of PTK787/ZK 222584, a 
specific, low molecular inhibitor of the VEGF receptor tyrosine kinases, when administered in 
combination with a routinely applied hypofractionated radiation scheme of four fractions of 6 
Gy. 
 
Our study revealed that pre-treatment with PTK787/ZK 222584 does not enhance the 
growth-retarding effect of ionizing radiation on our canine melanoma xenograft model. The 
tumour growth delay was similar in the combined treatment group and the radiation only 
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group, suggesting that the observed delay was only due to radiation therapy (Fig.1A). 
Previous in vitro studies suggested that four doses of PTK787/ZK 222584 combined with 
irradiation exert a potential radiosensitization and anti-proliferative effect on intra-tumoural 
endothelial cells resulting in a supra-additive, anti-tumoural effect on colon adenocarcinoma 
xenografts in nude mice (Hess et al., 2001). However, recent work showed no additional 
growth delay effect of PTK787/ZK 222584 when administered concomitantly before each 
fraction of radiation therapy (Zips et al., 2003). In contrast, when PTK787/ZK 222584 was 
applied in an adjuvant setting after the completion of a fractionated course of irradiation, it 
significantly inhibited tumour growth. Therefore, the optimal timing and sequencing of 
PTK787/ZK 222584 in the combined treatment of canine melanoma xenografts needs further 
investigation. 
 
We chose the treatment starting size of 500 mm3 to mimic the clinical situation with 
dogs having large, substantial tumours to be treated with radiation therapy. Our results 
indicate that treatment of already established malignant melanoma with PTK787/ZK 222584 
as a radiosensitizer is likely of limited success. This is in accordance with other studies 
suggesting that blocking growth signalling pathways in large tumours might be less effective 
than in small tumours (Sweeney et al., 2002; Yoshiji et al., 1997). The maturity of blood 
vessels appears to be another critical factor for the success of antiangiogenic therapy. 
Immature vessels, which lack pericyte coverage, are dependent on VEGF for survival, 
whereas solid tumours with mature vessels are less responsive (Benjamin et al., 1999).  
 
Since angiogenesis inhibitors act directly on endothelial cells and not tumour cells, 
clinical monitoring of tumour regression during therapy only partially reflects treatment 
efficacy. In the present study, power Doppler US was used to non-invasively assess tumour 
vascularity and perfusion during antiangiogenic therapy. Contrast-enhanced power Doppler 
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US has been shown to be the most sensitive Doppler technology for detecting low velocities 
and small parenchymal vessels e.g. in tumours (Schroeder et al., 2001). An additional 
advantage of power Doppler is the ability to survey the entire tumour vasculature reflecting 
anatomic and physiologic characteristics without perturbing the tumour being studied. Power 
Doppler US has also been described to monitor the effect of irradiation on tumour vasculature 
(Denis et al., 2003). In the present study, computerised image analysis was performed to 
determine the parameters FA (vascularity) and MCL and CWFA (perfusion). However, 
significant differences in vascularity and perfusion were found neither within nor between 
groups during and after treatment. Overall, baseline Doppler vascularity and perfusion in the 
tumours was low (Fig.2), which may have hampered the occurrence of significant differences 
during the course of treatment. In naturally occurring canine oral melanomas, our group found 
moderate vascularity and perfusion in contrast to highly vascularised and perfused squamous 
cell carcinomas and sarcomas with low vascularity and perfusion (Ohlerth et al., 2004). 
Therefore, the xenograft model used in the present study may not have adequately represented 
the biological vascularity and perfusion of canine oral melanomas. Interestingly, at the end of 
the experiment, all tumours were significantly less vascularised and perfused than prior to or 
during the course of treatment, but significant differences between treatment groups were not 
found. Depending on the tumour stage, perfusion and vascular pattern of a tumour may have a 
variable presentation. When tumours are small, high-flow states are a prominent feature 
because of arteriovenous shunts. As tumours enlarge, the high-flow areas become peripheral 
and poor perfusion in the central areas is common (Denis et al., 2003). 
Radiation has been shown to influence intra-tumoural pO2 values in experimental and clinical 
studies (Brizel et al., 1999; Nordsmark et al., 1996). Only few experimental studies in 
different rodent xenografts describe the oxygenation status during fractionated irradiation and 
illustrate the heterogeneity of serial changes in tumour oxygenation (Baumann et al., 2001; 
Stüben et al., 1999; Zywietz et al., 1995). There are only a few preclinical studies that 
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examined the effect of angiogenesis inhibitors combined with radiation therapy. The type of 
antiangiogenic drug that is being used and the tumour type might be of great importance for 
the effect on pO2 during a course of fractionated radiation, as shown in previous studies. (Lee 
et al., 2000; Teicher et al., 1995). To our knowledge, no study has addressed the kinetics of 
the oxygenation status when a combined therapy approach was used. We were therefore 
interested to evaluate how these therapies would influence the intra-tumoural oxygen tensions 
in canine melanoma xenografts. Pre-treatment, all tumours were severely hypoxic with a 
mean total pO2 of 2.4 mm Hg and a frequency distribution of values below 2.5 mm Hg of 
64% and values below 5 mm Hg of 86%. During and after completion of therapy, the 
oxygenation status remained unchanged (Table 1). As for the radiation therapy treated group, 
we confirmed previous results on human squamous cell carcinoma and rhabdomyosarcoma 
xenografts, where the pO2 did not change significantly during a course of fractionated 
radiation (Baumann et al., 2001; Zywietz et al., 1995). Although there was no improvement of 
the oxygenation status during therapy, one could argue that the oxygenation status does not 
impair with fractionated radiation therapy as seen by Teicher et. al. (1994) on studies on rat 
mammary carcinoma. Interestingly, the use of PTK787/ZK 222584 either alone or in 
combination had no influence on the pO2 and the frequency distribution of values below 2.5 
and 5 mm Hg. These results are in analogy with already mentioned studies using TNP-470 or 
neutralizing VEGF antibodies (Lee et al., 2000; Teicher et al., 1995).  
 
 
CONCLUSION 
 
In conclusion, the chosen radiation protocol effectively produced a growth delay in a 
canine oral melanoma xenograft model. When PTK787/ZK 222584 was used as a possible 
radiosenitiser in combination with fractionated radiation therapy, no additive effect on the 
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growth delay was seen. Further studies are clearly needed using smaller tumour treatment 
sizes along with a change of the drug schedule in relation to radiation therapy. In addition, the 
drug has to be assessed in more than one canine melanoma cell line to better outline its effect 
on canine patients suffering from oral malignant melanoma. Power Doppler and intra-
tumoural oxygen tension measurement are believed to be valuable tools in assessing treatment 
effect. 
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Table 1: Oxygenation of M2 melanoma xenografts during and after therapy 
 
Measurement a Group mean pO2 
(mmHg) b
Values (%) 
< 2.5 mmHg 
b
Values (%) 
< 5 mmHg b
Control 1.5 ± 0.7 76 ± 11 85 ± 7 
PTK787 c 3.2 ± 1.0 53 ± 12 68 ± 9 
RT d 1.0 ± 0.5 74 ± 6 81 ± 5 
Day 1 
RT + PTK787 c, d 3.5 ± 1.5 55 ± 13 62 ± 12 
     
Control 4.6 ± 2.2 44 ± 20 50 ± 20 
PTK787 3.7 ± 1.3 54 ± 14 61 ± 11 
RT 3.3 ± 1.9 60 ± 14 68 ± 12 
Day 4 
RT + PTK787 4.9 ± 1.6 40 ± 12 51 ± 13 
     
Control 4.2 ± 1.5 46 ± 12 68 ± 12 
PTK787 3.7 ± 2.4 61 ± 19 63 ± 19 
RT 2.7 ± 2.0 74 ± 14 81 ± 11 
Day 8 
RT + PTK787 2.3 ± 1.3 71 ± 10 77 ± 10 
     
Control 0.9 ± 0.3 82 ± 6 90 ± 4 
PTK787 1.8 ± 1.1 74 ± 9 84 ± 7 
RT 1.2 ± 0.6 80 ± 9 90 ± 6 
Day 12 
RT + PTK787 0.1 ± 0.0 98 ± 1 99 ± 1 
     
Control 2.3 ± 2.0 85 ± 9 86 ± 9 
PTK787 0.9 ± 0.9 80 ± 10 87 ± 7 
RT 1.9 ± 1.7 84 ± 9 86 ± 9 
End 
RT + PTK787 0.6 ± 0.6 86 ± 10 91 ± 7 
Table 1: Oxygenation of M2 melanoma xenografts during and after therapy  
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a Measurements were performed on days 1 and 4 of treatment, 4 and 8 days later and finally 
with an end size of 1500 ± 150 mm3  
b mean ± SE (n = 8-11 animals/group) 
c PTK787/ZK 222584 was administered at a dose of 100 mg/kg 
d Radiation therapy (RT) was given at a dose of 6 Gy/fraction
 19
 Figure legends 
 
Fig. 1: Tumour growth of differently treated M2 xenografts in nude mice. (A) Growth curves 
and (B) tumour growth delay. M2 canine melanoma cells (1x107) were inoculated 
subcutaneously within the left upper thigh region. Tumour treatment was started when the 
volume reached a size of 500 ± 50 mm3. On 4 consecutive days, mice were treated with 
PTK787/ZK 222584 (100mg/kg) and/or received radiation therapy (4 x 6 Gy) (see arrows). 
Tumour size was recorded twice a week until tumours reached a volume of 1500 ± 150 mm3. 
Each curve represents the mean tumour volume per group (n= 8-11 animals per group) ± SE.  
 
Fig. 2: Vascularity and perfusion during and after treatment. Contrast-enhanced power 
Doppler US was performed on day 1 and 4 of treatment (d1 and d4), 4 and 8 days after 
treatment (d8 and d12) and when tumours had reached the final size of 1500 ± 150 mm3 
(end). Overall tumour perfusion (CWFA) (A) and vascularity (FA) (B) were calculated. No 
significant differences in perfusion and vascularity were observed between and within 
treatment groups. *At the end of the study, perfusion and vascularity were significantly lower 
in all tumours (P = 0.0013 (CWFA) and P = 0.0002 (FA)).  
 
Fig. 3: Contrast-enhanced power Doppler US images of a representative M2 xenograft on day 
1 (start of therapy) (A) and at the end of the study (B). At the end of the study, vascularity and 
perfusion were significantly lower in all tumours. 
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